Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary

• Lisa H Butterfield,
• Howard Streicher,
• Patrick Hwu,
• Walter J Storkus,
• Ahmad A Tarhini,
• John M Kirkwood,
• F Stephen Hodi,
• Vernon K Sondak,
• Jose R Conejo-Garcia,
• Sandra J Lee,
• Aik-Choon Tan,
• Issam M El Naqa,
• William A LaFramboise,
• Arivarasan D Karunamurthy

Affiliations

Lisa H Butterfield

The Parker Institute for Cancer Immunotherapy, San Francisco, California, USA

Howard Streicher

Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, Maryland, USA

Patrick Hwu

Administration, Cutaneous Oncology, Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA

Walter J Storkus

Immunology, Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA

Ahmad A Tarhini

Cutaneous Oncology, Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA

John M Kirkwood

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA

F Stephen Hodi

Dana Farber Cancer Institute, Boston, Massachusetts, USA

Vernon K Sondak

Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA

Jose R Conejo-Garcia

Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA

Sandra J Lee

Biostatistics, Harvard Medical School, Boston, Massachusetts, USA

Aik-Choon Tan

Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA

Issam M El Naqa

Machine Learning, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA

William A LaFramboise

Pathology and Laboratory Medicine, Allegheny Cancer Institute, Allegheny Health Network, Pittsburgh, Pennsylvania, USA

Arivarasan D Karunamurthy

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA